|
시장보고서
상품코드
1421014
세계의 바이오의약품 CDMO 시장 : 인사이트와 예측(-2030년)Global Biopharmaceutical CDMO Market Insights, Forecast to 2030 |
||||||
QYResearch
세계의 바이오의약품 CDMO 시장 규모는 2024년 281억 6,000만 달러에서 예측기간 동안 13.14%의 CAGR로 성장하여 2030년에는 590억 5,000만 달러 규모로 성장할 것으로 예측됩니다.
세계의 바이오의약품 CDMO 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추정과 예측, 유형·용도별 내역, 지역·주요 국가별 상세 분석, 경쟁 환경, 시장 점유율, 순위, 주요 기업 개요 등을 정리했습니다.
목차
제1장 보고서 개요
- 조사 범위
- 시장 분석 : 유형별
- 성장률 : 2019 vs 2023 vs 2030
- 세포 및 유전자 치료
- 항체
- 백신
- 기타
- 용도별 시장
- 시장 점유율 : 2019 vs 2023 vs 2030
- 중소기업
- 대기업
- 가정과 제한
- 조사 목적
- 조사 기간
제2장 세계의 성장 동향
- 시장 전망
- 성장 동향 : 지역별
- 시장 규모 : 2019 vs 2023 vs 2030
- 시장 규모 추정
- 시장 규모 예측
- 시장 역학
- 업계 동향
- 시장 성장 촉진요인
- 시장 과제
- 시장 성장 억제요인
제3장 경쟁 상황 : 주요 기업별
- 매출·매출 점유율 : 기업별
- 시장 점유율 : 기업 유형별
- 세계 주요 기업 : 매출 순위
- 시장 집중률
- 세계의 주요 기업 : 본사 및 서비스 지역
- 세계의 주요 기업 : 참여일
- M&A·확장 계획
제4장 바이오의약품 CDMO 내역 데이터 : 유형별
- 시장 규모 추정과 예측
제5장 바이오의약품 CDMO 내역 데이터 : 용도별
- 시장 규모 추정과 예측
제6장 북미
제7장 유럽
제8장 아시아태평양
제9장 라틴아메리카
제10장 중동 및 아프리카
제11장 주요 기업 개요
- Lonza
- Catalent
- Samsung Biologics
- FUJIFILM Diosynth Biotechnologies
- Boehringer Ingelheim
- WuXi AppTech
- Recipharm
- Thermo Fisher
- AGC Biologics
- Rentschler Biopharma
- KBI Biopharma
- Siegfried
- Aenova Group
- GenScript
- ProBioGen
- Northway Biotech
- 3P Biopharmaceuticals
제12장 애널리스트에 의한 견해·결론
제13장 부록
KSM 24.02.15The global Biopharmaceutical CDMO market is projected to grow from US$ 28.16 billion in 2024 to US$ 59.05 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 13.14% during the forecast period.
Report Includes:
This report presents an overview of global market for Biopharmaceutical CDMO market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biopharmaceutical CDMO, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Biopharmaceutical CDMO, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biopharmaceutical CDMO revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Biopharmaceutical CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Biopharmaceutical CDMO revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, and AGC Biologics, etc.
Market Segmentation
By Company
- Lonza
- Catalent
- Samsung Biologics
- FUJIFILM Diosynth Biotechnologies
- Boehringer Ingelheim
- WuXi AppTech
- Recipharm
- Thermo Fisher Scientific
- AGC Biologics
- Rentschler Biopharma
- KBI Biopharma
- Siegfried
- Aenova Group
- GenScript
- ProBioGen
- Northway Biotech
- 3P Biopharmaceuticals
Segment by Type
- Cell and Gene Therapies
- Antibodies
- Vaccines
- Other
Segment by Application
- SMBs
- Large Companies
By Region
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of APAC
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Rest of Europe
- Latin America
- Brazil
- Argentina
- Colombia
- Rest of Latin America
- Middle East & Africa
- Middle East
- Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Biopharmaceutical CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biopharmaceutical CDMO companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: Asia-Pacific by Type, and by Application, revenue for each segment.
Chapter 9: Latin America by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biopharmaceutical CDMO revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
- 1.2.2 Cell and Gene Therapies
- 1.2.3 Antibodies
- 1.2.4 Vaccines
- 1.2.5 Other
- 1.3 Market by Application
- 1.3.1 Global Biopharmaceutical CDMO Market Share by Application: 2019 VS 2023 VS 2030
- 1.3.2 SMBs
- 1.3.3 Large Companies
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Biopharmaceutical CDMO Market Perspective (2019-2030)
- 2.2 Global Biopharmaceutical CDMO Growth Trends by Region
- 2.2.1 Global Biopharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
- 2.2.2 Biopharmaceutical CDMO Historic Market Size by Region (2019-2024)
- 2.2.3 Biopharmaceutical CDMO Forecasted Market Size by Region (2025-2030)
- 2.3 Biopharmaceutical CDMO Market Dynamics
- 2.3.1 Biopharmaceutical CDMO Industry Trends
- 2.3.2 Biopharmaceutical CDMO Market Drivers
- 2.3.3 Biopharmaceutical CDMO Market Challenges
- 2.3.4 Biopharmaceutical CDMO Market Restraints
3 Competition Landscape by Key Players
- 3.1 Global Revenue Biopharmaceutical CDMO by Players
- 3.1.1 Global Biopharmaceutical CDMO Revenue by Players (2019-2024)
- 3.1.2 Global Biopharmaceutical CDMO Revenue Market Share by Players (2019-2024)
- 3.2 Global Biopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Global Key Players of Biopharmaceutical CDMO, Ranking by Revenue, 2022 VS 2023
- 3.4 Global Biopharmaceutical CDMO Market Concentration Ratio
- 3.4.1 Global Biopharmaceutical CDMO Market Concentration Ratio (CR5)
- 3.4.2 Global Top 5 and Top 10 Companies by Biopharmaceutical CDMO Revenue in 2023
- 3.5 Global Key Players of Biopharmaceutical CDMO Head office and Area Served
- 3.6 Global Key Players of Biopharmaceutical CDMO, Date of Enter into This Industry
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Biopharmaceutical CDMO Breakdown Data by Type
- 4.1 Global Biopharmaceutical CDMO Historic Market Size by Type (2019-2024)
- 4.2 Global Biopharmaceutical CDMO Forecasted Market Size by Type (2025-2030)
5 Biopharmaceutical CDMO Breakdown Data by Application
- 5.1 Global Biopharmaceutical CDMO Historic Market Size by Application (2019-2024)
- 5.2 Global Biopharmaceutical CDMO Forecasted Market Size by Application (2025-2030)
6 North America
- 6.1 North America Biopharmaceutical CDMO Market Size (2019-2030)
- 6.2 North America Biopharmaceutical CDMO Market Size by Type
- 6.2.1 North America Biopharmaceutical CDMO Market Size by Type (2019-2024)
- 6.2.2 North America Biopharmaceutical CDMO Market Size by Type (2025-2030)
- 6.2.3 North America Biopharmaceutical CDMO Market Share by Type (2019-2030)
- 6.3 North America Biopharmaceutical CDMO Market Size by Application
- 6.3.1 North America Biopharmaceutical CDMO Market Size by Application (2019-2024)
- 6.3.2 North America Biopharmaceutical CDMO Market Size by Application (2025-2030)
- 6.3.3 North America Biopharmaceutical CDMO Market Share by Application (2019-2030)
- 6.4 North America Biopharmaceutical CDMO Market Size by Country
- 6.4.1 North America Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
- 6.4.2 North America Biopharmaceutical CDMO Market Size by Country (2019-2024)
- 6.4.3 North America Biopharmaceutical CDMO Market Share by Country (2025-2030)
- 6.4.4 United States
- 6.4.5 Canada
- 6.4.6 Mexico
7 Europe
- 7.1 Europe Biopharmaceutical CDMO Market Size (2019-2030)
- 7.2 Europe Biopharmaceutical CDMO Market Size by Type
- 7.2.1 Europe Biopharmaceutical CDMO Market Size by Type (2019-2024)
- 7.2.2 Europe Biopharmaceutical CDMO Market Size by Type (2025-2030)
- 7.2.3 Europe Biopharmaceutical CDMO Market Share by Type (2019-2030)
- 7.3 Europe Biopharmaceutical CDMO Market Size by Application
- 7.3.1 Europe Biopharmaceutical CDMO Market Size by Application (2019-2024)
- 7.3.2 Europe Biopharmaceutical CDMO Market Size by Application (2025-2030)
- 7.3.3 Europe Biopharmaceutical CDMO Market Share by Application (2019-2030)
- 7.4 Europe Biopharmaceutical CDMO Market Size by Country
- 7.4.1 Europe Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
- 7.4.2 Europe Biopharmaceutical CDMO Market Size by Country (2019-2024)
- 7.4.3 Europe Biopharmaceutical CDMO Market Size by Country (2025-2030)
- 7.4.4 Germany
- 7.4.5 France
- 7.4.6 U.K.
- 7.4.7 Italy
- 7.4.8 Russia
8 Asia-Pacific
- 8.1 Asia-Pacific Biopharmaceutical CDMO Market Size (2019-2030)
- 8.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Type
- 8.2.1 Asia-Pacific Biopharmaceutical CDMO Market Size by Type (2019-2024)
- 8.2.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Type (2025-2030)
- 8.2.3 Asia-Pacific Biopharmaceutical CDMO Market Share by Type (2019-2030)
- 8.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Application
- 8.3.1 Asia-Pacific Biopharmaceutical CDMO Market Size by Application (2019-2024)
- 8.3.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Application (2025-2030)
- 8.3.3 Asia-Pacific Biopharmaceutical CDMO Market Share by Application (2019-2030)
- 8.4 Asia-Pacific Biopharmaceutical CDMO Market Size by Region
- 8.4.1 Asia-Pacific Biopharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
- 8.4.2 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2019-2024)
- 8.4.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2025-2030)
- 8.4.4 China
- 8.4.5 Japan
- 8.4.6 South Korea
- 8.4.7 Southeast Asia
- 8.4.8 India
- 8.4.9 Australia
9 Latin America
- 9.1 Latin America Biopharmaceutical CDMO Market Size (2019-2030)
- 9.2 Latin America Biopharmaceutical CDMO Market Size by Type
- 9.2.1 Latin America Biopharmaceutical CDMO Market Size by Type (2019-2024)
- 9.2.2 Latin America Biopharmaceutical CDMO Market Size by Type (2025-2030)
- 9.2.3 Latin America Biopharmaceutical CDMO Market Share by Type (2019-2030)
- 9.3 Latin America Biopharmaceutical CDMO Market Size by Application
- 9.3.1 Latin America Biopharmaceutical CDMO Market Size by Application (2019-2024)
- 9.3.2 Latin America Biopharmaceutical CDMO Market Size by Application (2025-2030)
- 9.3.3 Latin America Biopharmaceutical CDMO Market Share by Application (2019-2030)
- 9.4 Latin America Biopharmaceutical CDMO Market Size by Country
- 9.4.1 Latin America Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
- 9.4.2 Latin America Biopharmaceutical CDMO Market Size by Country (2019-2024)
- 9.4.3 Latin America Biopharmaceutical CDMO Market Size by Country (2025-2030)
- 9.4.4 Brazil
- 9.4.5 Argentina
- 9.4.6 Colombia
10 Middle East and Africa
- 10.1 Middle East and Africa Biopharmaceutical CDMO Market Size (2019-2030)
- 10.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Type
- 10.2.1 Middle East and Africa Biopharmaceutical CDMO Market Size by Type (2019-2024)
- 10.2.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Type (2025-2030)
- 10.2.3 Middle East and Africa Biopharmaceutical CDMO Market Share by Type (2019-2030)
- 10.3 Middle East and Africa Biopharmaceutical CDMO Market Size by Application
- 10.3.1 Middle East and Africa Biopharmaceutical CDMO Market Size by Application (2019-2024)
- 10.3.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Application (2025-2030)
- 10.3.3 Middle East and Africa Biopharmaceutical CDMO Market Share by Application (2019-2030)
- 10.4 Middle East and Africa Biopharmaceutical CDMO Market Size by Country
- 10.4.1 Middle East and Africa Biopharmaceutical CDMO Market Size by Country: 2019 VS 2023 VS 2030
- 10.4.2 Middle East and Africa Biopharmaceutical CDMO Market Size by Country (2019-2024)
- 10.4.3 Middle East and Africa Biopharmaceutical CDMO Market Size by Country (2025-2030)
- 10.4.4 Middle East
- 10.4.5 Africa
11 Key Players Profiles
- 11.1 Lonza
- 11.1.1 Lonza Company Details
- 11.1.2 Lonza Business Overview
- 11.1.3 Lonza Biopharmaceutical CDMO Introduction
- 11.1.4 Lonza Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.1.5 Lonza Recent Development
- 11.2 Catalent
- 11.2.1 Catalent Company Details
- 11.2.2 Catalent Business Overview
- 11.2.3 Catalent Biopharmaceutical CDMO Introduction
- 11.2.4 Catalent Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.2.5 Catalent Recent Development
- 11.3 Samsung Biologics
- 11.3.1 Samsung Biologics Company Details
- 11.3.2 Samsung Biologics Business Overview
- 11.3.3 Samsung Biologics Biopharmaceutical CDMO Introduction
- 11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.3.5 Samsung Biologics Recent Development
- 11.4 FUJIFILM Diosynth Biotechnologies
- 11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
- 11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Introduction
- 11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
- 11.5 Boehringer Ingelheim
- 11.5.1 Boehringer Ingelheim Company Details
- 11.5.2 Boehringer Ingelheim Business Overview
- 11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Introduction
- 11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.5.5 Boehringer Ingelheim Recent Development
- 11.6 WuXi AppTech
- 11.6.1 WuXi AppTech Company Details
- 11.6.2 WuXi AppTech Business Overview
- 11.6.3 WuXi AppTech Biopharmaceutical CDMO Introduction
- 11.6.4 WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.6.5 WuXi AppTech Recent Development
- 11.7 Recipharm
- 11.7.1 Recipharm Company Details
- 11.7.2 Recipharm Business Overview
- 11.7.3 Recipharm Biopharmaceutical CDMO Introduction
- 11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.7.5 Recipharm Recent Development
- 11.8 Thermo Fisher
- 11.8.1 Thermo Fisher Company Details
- 11.8.2 Thermo Fisher Business Overview
- 11.8.3 Thermo Fisher Biopharmaceutical CDMO Introduction
- 11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.8.5 Thermo Fisher Recent Development
- 11.9 AGC Biologics
- 11.9.1 AGC Biologics Company Details
- 11.9.2 AGC Biologics Business Overview
- 11.9.3 AGC Biologics Biopharmaceutical CDMO Introduction
- 11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.9.5 AGC Biologics Recent Development
- 11.10 Rentschler Biopharma
- 11.10.1 Rentschler Biopharma Company Details
- 11.10.2 Rentschler Biopharma Business Overview
- 11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Introduction
- 11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.10.5 Rentschler Biopharma Recent Development
- 11.11 KBI Biopharma
- 11.11.1 KBI Biopharma Company Details
- 11.11.2 KBI Biopharma Business Overview
- 11.11.3 KBI Biopharma Biopharmaceutical CDMO Introduction
- 11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.12 Siegfried
- 11.12.1 Siegfried Company Details
- 11.12.2 Siegfried Business Overview
- 11.12.3 Siegfried Biopharmaceutical CDMO Introduction
- 11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.12.5 Siegfried Recent Development
- 11.13 Aenova Group
- 11.13.1 Aenova Group Company Details
- 11.13.2 Aenova Group Business Overview
- 11.13.3 Aenova Group Biopharmaceutical CDMO Introduction
- 11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.14 GenScript
- 11.14.1 GenScript Company Details
- 11.14.2 GenScript Business Overview
- 11.14.3 GenScript Biopharmaceutical CDMO Introduction
- 11.14.4 GenScript Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.14.5 GenScript Recent Development
- 11.15 ProBioGen
- 11.15.1 ProBioGen Company Details
- 11.15.2 ProBioGen Business Overview
- 11.15.3 ProBioGen Biopharmaceutical CDMO Introduction
- 11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.16 Northway Biotech
- 11.16.1 Northway Biotech Company Details
- 11.16.2 Northway Biotech Business Overview
- 11.16.3 Northway Biotech Biopharmaceutical CDMO Introduction
- 11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Business (2019-2024)
- 11.16.5 Northway Biotech Recent Development
- 11.17 3P Biopharmaceuticals
- 11.17.1 3P Biopharmaceuticals Company Details
- 11.17.2 3P Biopharmaceuticals Business Overview
- 11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Introduction
- 11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2019-2024)
12 Analyst's Viewpoints/Conclusions
13 Appendix
- 13.1 Research Methodology
- 13.1.1 Methodology/Research Approach
- 13.1.2 Data Source
- 13.2 Author Details
- 13.3 Disclaimer
